Jul 2026· Journal of Receptor and Signal Transduction Research· Vol 46, pp. 168 - 177· 0 citations· 37 references
Medicine
TL;DR
Findings support further investigation of phycobiliproteins as potential sources of bioactive compounds for functional food and nutraceutical applications targeting AD-related pathways.
Abstract
Abstract Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, Tau hyperphosphorylation, and cholinergic dysfunction, necessitating multi-target therapeutic strategies. This study evaluated phycobiliproteins (PBPs) as dietary precursors of neuroprotective compounds acting on multiple AD pathways. After simulated gastrointestinal digestion, peptide fractions P1 (GCAPR), P2 (QAGDQL), and P3 (AGDASVL) were assessed alongside phycocyanobilin (PCB) using molecular docking against Beta-secretase 1, Glycogen synthase kinase 3 beta, Acetylcholinesterase, and Butyrylcholinesterase. PCB showed strong affinities toward BChE (–10.0 kcal/mol) and GSK-3β (–8.4 kcal/mol), suggesting modulation of tauopathic and late-stage cholinergic pathways. P2 exhibited notable binding to AChE (–8.8 kcal/mol) and BACE1 (–7.6 kcal/mol), indicating effects on amyloidogenic and early cholinergic mechanisms, while P1 and P3 provided complementary moderate activity. Overall, these findings support further investigation of PBPs as potential sources of bioactive compounds for functional food and nutraceutical applications targeting AD-related pathways.
Tilianin is a promising dual-site AChE inhibitor candidate that may simultaneously improve cholinergic neurotransmission and reduce β-amyloid (Aβ) aggregation against AD, and further in vitro and in vivo validation studies are required to confirm its therapeutic potential.
Dini Attala Hefa Insyira, T. Tukiran· JURNAL PIJAR MIPA· 0 citations
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder accounting for 60-70% of dementia cases globally, with the β-site amyloid precursor protein cleaving enzyme-1 (BACE-1) representing one of the most intensively studied therapeutic targets due to its rate-limiting role in amyloid-β (Aβ) peptide product...
Pratham Jha, S. Saxena· Natural Product Research· 0 citations
Background: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) regulate cholinergic neurotransmission and remain relevant targets for symptomatic treatment and ligand discovery in Alzheimer's disease. This study comparatively screened 16 phytochemicals from six medicinal plants against human AChE and BChE. Me...
S. Yılmaz, Şeyma Yaşar· Anatolian Journal of Pharmac...· 0 citations
Several of the identified multitarget phytochemicals are promising candidates for further experimental validation in AD therapy and supported by the literature, which shows that they can inhibit amyloid aggregation, tau phosphorylation, neuroinflammation, and cholinergic dysfunction.
Samuel Mesfin, N. Bloch, Abraham O. Samson· Frontiers in Drug Discovery· 0 citations
Introduction: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder for which single-target strategies may be insufficient. This study explored a host–microbial multitarget strategy using a CNS-oriented small molecule predicted to engage both human acetylcholinesterase (AChE) and Porphyromonas gingiva...
Ahmad M. Sait, Philip J. R. Day· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.